Mylan Specialty Revenue and Competitors

Napa, CA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Mylan Specialty's estimated annual revenue is currently $62.7M per year.(i)
  • Mylan Specialty's estimated revenue per employee is $201,000

Employee Data

  • Mylan Specialty has 312 Employees.(i)
  • Mylan Specialty grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.4M2-67%N/AN/A
#2
$32M1593%N/AN/A
#3
$35M1213%$62.5MN/A
#4
$30.2M15018%N/AN/A
#5
$135.9M676-1%N/AN/A
#6
$14.9M972%$173MN/A
#7
$110.3M549N/AN/AN/A
#8
$62.7M312-3%N/AN/A
#9
$4.9M4932%N/AN/A
#10
$9.2M46-2%N/AN/A
Add Company

Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers.

keywords:N/A

N/A

Total Funding

312

Number of Employees

$62.7M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mylan Specialty News

2022-04-13 - Mylan Pharmaceuticals Issues Voluntary Recall of Insulin ...

Bhd and was distributed by Mylan Specialty L.P. in the United States between Dec. 9, 2021 and March 4, 2022. A missing label on Insulin Glargine...

2022-04-06 - Mylan Pharmaceuticals Inc., a Viatris Company, Conducting ...

This batch was manufactured by Biocon Sdn. Bhd. and was distributed by Mylan Specialty L.P. in the US between December 9, 2021, and March 4,...

2022-04-06 - The mysterious case of Viatris and the missing insulin label ...

Mylan Pharmaceuticals, now flying the Viatris banner, said Tuesday that it ... by India's Biocon and distributed nationwide by Mylan Specialty between Dec.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M324-9%$10.3M
#2
$125.4M346-3%N/A
#3
$69.6M38417%N/A
#4
$83.8M44726%N/A
#5
$129.2M574N/AN/A